Stock FBLG FIBROBIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

FibroBiologics, Inc. Stock

Equities

FBLG

US31573L1052

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
6.72 USD -15.26% Intraday chart for FibroBiologics, Inc. -41.67% 0.00%
Apr. 25 FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids CI
Apr. 04 Fibrobiologics Presents Data from Dermal Fibroblast Spheroid-Based Treatment of Chronic Wounds in A Diabetes Mouse Model At Advanced Wound Care Summit USA CI

Financials (USD)

Sales 2022 - Sales 2023 - Capitalization 258M
Net income 2022 -5M Net income 2023 -16M EV / Sales 2022 * -
Net cash position 2022 * - Net cash position 2023 * - EV / Sales 2023 * -
P/E ratio 2022 *
-
P/E ratio 2023 *
-
Employees 10
Yield 2022 *
-
Yield 2023 *
-
Free-Float 69.67%
More Fundamentals * Assessed data

Chart FibroBiologics, Inc.

Dynamic Chart

Latest news about FibroBiologics, Inc.

FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids CI
Fibrobiologics Presents Data from Dermal Fibroblast Spheroid-Based Treatment of Chronic Wounds in A Diabetes Mouse Model At Advanced Wound Care Summit USA CI
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply MT
FibroBiologics, Inc. Appoints Ruben A. Garcia as General Counsel CI
FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Top Premarket Gainers MT
FibroBiologics, Inc. to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis Forum CI
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases CI
Top Premarket Gainers MT
FibroBiologics, Inc.(NasdaqGM:FBLG) added to NASDAQ Composite Index CI
More news

Press releases FibroBiologics, Inc.

FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids GL
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office GL
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA GL
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus GL
FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment PR
More press releases

Quotes and Performance

1 day-15.91%
1 week-31.16%
Current month-15.91%
1 month-30.50%
3 months-54.69%
More quotes

Highs and lows

1 week
7.79
Extreme 7.79
11.20
1 month
7.79
Extreme 7.79
11.75
Current year
6.53
Extreme 6.53
55.00
1 year
6.53
Extreme 6.53
55.00
3 years
6.53
Extreme 6.53
55.00
5 years
6.53
Extreme 6.53
55.00
10 years
6.53
Extreme 6.53
55.00
More quotes

Managers and Directors - FibroBiologics, Inc.

Managers TitleAgeSince
Peter O'Heeron CEO
 Chief Executive Officer 61 21-04-07
Mark Andersen DFI
 Director of Finance/CFO 53 22-05-31
Hamid Khoja CTO
 Chief Tech/Sci/R&D Officer 55 21-07-31
Members of the board TitleAgeSince
Robert Hoffman BRD
 Director/Board Member 58 21-04-07
Richard C. Cilento BRD
 Director/Board Member 61 21-04-07
Peter O'Heeron CEO
 Chief Executive Officer 61 21-04-07
More insiders

Company Profile

FibroBiologics Inc is a United States-based company. The Company operates as a biopharmaceutical company. It is focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. It also develops biologic cures and treatments for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing, and cancer, and anti-aging extension of life applications such as thymic involution reversal and splenic involution reversal.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
FIBROBIOLOGICS, INC. Stock FibroBiologics, Inc.
0.00% 258M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.17% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.87% 97.47B
ARGENX SE Stock argenx SE
+4.40% 22.25B
BIONTECH SE Stock BioNTech SE
-14.77% 21.68B
GENMAB A/S Stock Genmab A/S
-8.70% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.55% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.75% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. FBLG Stock